PlainRecalls
FDA Drug Moderate Class II Terminated

Testosterone Cypionate Injection, USP, CIII, 200 mg/mL, packaged in: a) 10 mL multiple-dose vials (NDC 52536-625-10) and b) 1 mL single dose vials (NDC 52536-625-01), Rx only, Mfd for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328.

Reported: April 12, 2023 Initiated: February 15, 2023 #D-0489-2023

Product Description

Testosterone Cypionate Injection, USP, CIII, 200 mg/mL, packaged in: a) 10 mL multiple-dose vials (NDC 52536-625-10) and b) 1 mL single dose vials (NDC 52536-625-01), Rx only, Mfd for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328.

Reason for Recall

cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.

Details

Units Affected
a) 16,471 vials; b) 43,096 vials
Distribution
US Nationwide
Location
Wilmington, MA

Frequently Asked Questions

What product was recalled?
Testosterone Cypionate Injection, USP, CIII, 200 mg/mL, packaged in: a) 10 mL multiple-dose vials (NDC 52536-625-10) and b) 1 mL single dose vials (NDC 52536-625-01), Rx only, Mfd for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328.. Recalled by Azurity Pharmaceuticals, Inc.. Units affected: a) 16,471 vials; b) 43,096 vials.
Why was this product recalled?
cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 12, 2023. Severity: Moderate. Recall number: D-0489-2023.